Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Acquires Stock Options and Restricted Stock Units
SEC Form 4
Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, acquired stock options and restricted stock units on March 7, 2024.
Summary
- On March 7, 2024, Bobak R. Azamian, the President/CEO and Board Chair of Tarsus Pharmaceuticals, acquired 136,947 stock options with an exercise price of $35.50 and 92,485 restricted stock units (RSUs).
- The stock options vest over a four-year period, with 25% vesting on March 7, 2025, and the remaining 75% vesting monthly over the subsequent three years, contingent upon continuous service.
- The RSUs also vest over a four-year period, with 25% vesting on March 15th of each of 2025, 2026, 2027, and 2028, subject to continuous service.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports factual information about executive compensation.
Positives
- The vesting schedules for both the stock options and RSUs incentivize long-term commitment from the CEO.
Future Outlook
The document does not contain any specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, common in the pharmaceutical industry as part of executive compensation packages.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Vesting schedules of four years are typical to align executive interests with long-term company performance.
- Comparing the size of the grant to similar companies like дермаеutics or Galderma would provide context on whether the grant is above or below industry averages for CEOs.
Stakeholder Impact
- The stock options and RSUs align the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: Acquisition of stock options and restricted stock units. |
| 03/07/2025 | First vesting date for 25% of the stock options. |
| 03/15/2025 | First vesting date for 25% of the RSUs. |
| 03/06/2034 | Expiration date of the stock options. |
| 03/11/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.